Lithium Ion

Lithium Ion

SCHEMBL462265

CC(C)(C)c1ccc(N2CCC(CCC(=O)[O-])CC2)cc1.[Li+]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.48
HSD11B1 P28845 5/20 0.44
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
PTGER3 P43115 1/20 0.40
PTGER2 P43116 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL463205 0.92 HRH3 (0.46) HRH3HSD11B1MAPTLMNACNR1
SCHEMBL12042054 0.87 HRH3 (0.51) HRH3HSD11B1MAPTLMNACNR1
Lithium Ion SCHEMBL382243 0.86 NOTUM (0.52) HRH3CA12CA2CA9
SCHEMBL462264 0.86 HRH3 (0.50) HRH3HSD11B1MAPTLMNACNR1
Lithium Ion SCHEMBL381917 0.83 NOTUM (0.48) MAPTLMNAALDH1A1KDM4EHTT
SCHEMBL462291 0.83 HRH3 (0.47) HRH3HSD11B1MAPTLMNACNR1
SCHEMBL12042028 0.81 PTGER2 (0.54) HRH3HSD11B1MAPTLMNAALDH1A1
SCHEMBL463204 0.80 PTGER2 (0.53) HRH3HSD11B1MAPTLMNAALDH1A1
Lithium Ion SCHEMBL9983843 0.80 MEN1 (0.47) HRH3HSD11B1MAPTLMNAALDH1A1
Lithium Ion SCHEMBL381807 0.79 NOTUM (0.50) HRH3CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
EP-2408742-A1 ANTHELMINTIC AGENTS AND THEIR USE Intervet International B.V. (NL) 2012-01-25 EP disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO HRH3 311/4885HSD11B1 2791/4885MAPT 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.